Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

JNCE

Jounce Therapeutics (JNCE)

Jounce Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:JNCE
FechaHoraFuenteTítuloSímboloCompañía
14/02/202407:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JNCEJounce Therapeutics Inc
15/05/202306:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202315:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202315:35Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202305:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202307:40Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:31Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:JNCEJounce Therapeutics Inc
03/05/202319:35GlobeNewswire Inc.Jounce Therapeutics Announces Closing of Tender OfferNASDAQ:JNCEJounce Therapeutics Inc
28/04/202313:48Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202306:55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202301:00GlobeNewswire Inc.Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNASDAQ:JNCEJounce Therapeutics Inc
27/03/202313:12Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:JNCEJounce Therapeutics Inc
27/03/202308:00GlobeNewswire Inc.Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNASDAQ:JNCEJounce Therapeutics Inc
16/03/202315:30GlobeNewswire Inc.Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerNASDAQ:JNCEJounce Therapeutics Inc
14/03/202320:00GlobeNewswire Inc.Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:JNCEJounce Therapeutics Inc
14/03/202316:01Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:JNCEJounce Therapeutics Inc
10/03/202308:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:JNCEJounce Therapeutics Inc
06/03/202315:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202315:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202301:30GlobeNewswire Inc.Redx and Jounce Announce Recommended Business CombinationNASDAQ:JNCEJounce Therapeutics Inc
22/02/202316:00GlobeNewswire Inc.Jounce Therapeutics Announces RestructuringNASDAQ:JNCEJounce Therapeutics Inc
14/02/202315:55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:JNCEJounce Therapeutics Inc
09/01/202305:02Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:JNCEJounce Therapeutics Inc
27/12/202216:24Dow Jones NewsGilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202215:30Business WireGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202215:30GlobeNewswire Inc.Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
08/12/202206:50GlobeNewswire Inc.Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNASDAQ:JNCEJounce Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JNCE